"Prescription Fees" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The charge levied on the consumer for drugs or therapy prescribed under written order of a physician or other health professional.
| Descriptor ID |
D011306
|
| MeSH Number(s) |
N03.219.442.551.621
|
| Concept/Terms |
Prescription Fees- Prescription Fees
- Dispensing Fees
- Dispensing Fee
- Fee, Dispensing
- Fees, Dispensing
- Fees, Prescription
- Fee, Prescription
- Prescription Fee
|
Below are MeSH descriptors whose meaning is more general than "Prescription Fees".
Below are MeSH descriptors whose meaning is more specific than "Prescription Fees".
This graph shows the total number of publications written about "Prescription Fees" by people in this website by year, and whether "Prescription Fees" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 3 | 5 |
| 2019 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Prescription Fees" by people in Profiles.
-
Drug pricing in the USA. Lancet Respir Med. 2019 11; 7(11):937.
-
Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2020 Jan; 23(1):37-47.
-
Ongoing initiatives within the Scottish National Health Service to affect the prescribing of selective serotonin reuptake inhibitors and their influence. J Comp Eff Res. 2019 05; 8(7):535-547.
-
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer. 2018 11; 104:201-209.
-
Changes in Drug Pricing After Drug Shortages in the United States. Ann Intern Med. 2019 01 01; 170(1):74-76.
-
Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D. JAMA. 2018 09 04; 320(9):931-933.
-
An Incomplete Prescription: President Trump's Plan to Address High Drug Prices. JAMA. 2018 06 19; 319(23):2373-2374.
-
Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study. BMJ. 2018 03 19; 360:k831.
-
The Price of Crossing the Border for Medications. N Engl J Med. 2017 Jul 27; 377(4):311-313.